Resumo

ROMERO-PRADA, Martín Emilio et al. Cost-Utility Analysis of the Use of Detemir in Patients with Type 2 Diabetes. Rev. Gerenc. Polit. Salud [online]. 2015, vol.14, n.28, pp.190-201. ISSN 1657-7027.  https://doi.org/10.11144/Javeriana.rgyps18-28.acuu.

Objective: Performing a cost-utility analysis to assess the treatment with different insulin options in patients with Type 2 Diabetes. Methodology: Based on the analysis previously performed by Romero et al., we updated the information and included an specific analysis for the quality of life. The Markov model simulated patients treated with NPH, determir, or glargine insulin. We considered the hypoglycemia events and their complications. The costs corresponded to the maximum regulated price per dose. The event costs were taken from the transaction information system records of health care providers in 2014. Results: The qaly with detemir are calculated as 2.604, compared to 2.545 with glargine, and 2.533 con NPH. The sensitivity analysis show determir dominance. Conclusions: Detemir is a favorable option due to its safety, effectiveness, and cost, with proven benefits measured in qaly over the other items being compared.

Palavras-chave : diabetes mellitus type 2; insulin; quality of life; cost-utility analysis; effectiveness.

        · resumo em Português | Espanhol     · texto em Espanhol     · Espanhol ( pdf )